Skip to main content
Premium Trial:

Request an Annual Quote

Sanofi to Test Vaccine Candidate

Sanofi is launching a clinical trial of a candidate mRNA-based vaccine for SARS-CoV-2, the Financial Times reports.

It notes that Sanofi originally focused in conjunction with GlaxoSmithKline on a SARS-CoV-2 vaccine based on recombinant protein. But the two companies reported in December that their candidate vaccine raised an insufficient immune response in early-stage clinical trials, delaying their timeline.

But as Barron's reports, Sanofi has also been working with US-based Translate Bio on an mRNA-based vaccine, like those from Pfizer-BioNTech and Moderna. Sanofi and Translate are now starting a Phase 1/2 trial into which they plan to enroll 415 participants to assess the candidate vaccine's safety, dosing, and possible side effects, according to Forbes. It adds that the companies expect interim results by the third quarter of the year.

Sanofi and Translate are also beginning early-stage studies of other candidate vaccines aimed at SARS-CoV-2 variants, FT adds.

It notes that France has viewed the inability of Sanofi or the Pasteur Institute — which ended its vaccine effort in January following disappointing results — to bring a vaccine to market as a national embarrassment.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.